

## FREEDOM OF INFORMATION REQUEST

RF23-459

### Request:

Q1. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of melanoma?

- Ipilimumab (monotherapy)
- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination)
- Pembrolizumab
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated\* on the following agents for the treatment of renal cell carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated\* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:

- Nivolumab monotherapy or in combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.



**Response:**

We can confirm East Kent Hospitals University NHS Foundation Trust (EKHUFT) holds the information you have requested.

1.

Ipilimumab (monotherapy)	0
Nivolumab (monotherapy)	<5*
Nivolumab AND Ipilimumab (combination)	<5*
Pembrolizumab	13
Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	5
Other active systemic anti-cancer therapy	<5*

2.

Nivolumab (monotherapy)	0
Nivolumab + Ipilimumab	<5*
Nivolumab + Cabozantinib	0
Avelumab + Axitinib	<5*

3.

Nivolumab monotherapy or in combination with Ipilimumab	<5*
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)	0
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)	<5*

**(DATE OF RESPONSE: 04 AUGUST 2023)**

